Immutep Reports Promising New Data in Head and Neck Cancer
Filed with ASX · · 3 pages · English
• Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1 • Positively, median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%, both well above historical controls • Complete response rate increases to 12.9% and
Story so far
Earlier from Immutep
- Initiation of TACTI-004 phase 3 trial in 1st line NSCLC
- Excellent Survival Data from INSIGHT-003 Trial in NSCLC
- Positive Data from Phase II Trial in Soft Tissue Sarcoma
- Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed
- Immutep receives A$3.6 million French R&D Tax Incentive
Later from Immutep
- Immutep announces initial safety data from IMP761 phase 1
- Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
- First patient dosed in phase 3 TACTI-004 lung cancer trial
- First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
- Immutep to Participate in Upcoming Investor Conferences
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep